A phase 2 clinical trialâ¯assessing theâ¯efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer.

Ho, Alice Y; Barker, Christopher A; Arnold, Brittany B; Powell, Simon N; Hu, Zishuo I; Gucalp, Ayca; Lebron-Zapata, Lizza; Wen, Hannah Y; Kallman, Cindy; D'Agnolo, Alessandro; Zhang, Zhigang; Flynn, Jessica; Dunn, Samantha A; McArthur, Heather L

A phase 2 clinical trialâ¯assessing theâ¯efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer.

Ho, Alice Y; Barker, Christopher A; Arnold, Brittany B; Powell, Simon N; Hu, Zishuo I; Gucalp, Ayca; Lebron-Zapata, Lizza; Wen, Hannah Y; Kallman, Cindy; D'Agnolo, Alessandro; Zhang, Zhigang; Flynn, Jessica; Dunn, Samantha A; McArthur, Heather L.

Afiliación

Ho AY; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Barker CA; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Arnold BB; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Powell SN; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Hu ZI; Medical Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Gucalp A; Medical Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Lebron-Zapata L; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Wen HY; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Kallman C; Department of Radiology, Cedars-Sinai Medical Center, Los Angeles, California.
D'Agnolo A; Department of Radiology, Cedars-Sinai Medical Center, Los Angeles, California.
Zhang Z; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Flynn J; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Dunn SA; Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts.
McArthur HL; Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California.

Cancer ; 126(4): 850-860, 2020 02 15.

Article en En | MEDLINE | ID: mdl-31747077

Asunto(s)

Anticuerpos Monoclonales Humanizados/uso terapéutico; Radioterapia/métodos; Neoplasias de la Mama Triple Negativas/terapia; Adulto; Anciano; Anticuerpos Monoclonales Humanizados/efectos adversos; Antineoplásicos Inmunológicos/efectos adversos; Antineoplásicos Inmunológicos/uso terapéutico; Quimioradioterapia/efectos adversos; Quimioradioterapia/métodos; Estudios de Cohortes; Dermatitis/etiología; Fatiga/etiología; Femenino; Humanos; Estimación de Kaplan-Meier; Linfopenia/etiología; Persona de Mediana Edad; Receptor de Muerte Celular Programada 1/antagonistas & inhibidores; Receptor de Muerte Celular Programada 1/metabolismo; Radioterapia/efectos adversos; Resultado del Tratamiento; Neoplasias de la Mama Triple Negativas/metabolismo; Neoplasias de la Mama Triple Negativas/patología

Palabras clave

checkpoint blockade; immunotherapy; metastatic; radiotherapy (RT); triple-negative breast cancer (TNBC)

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Radioterapia / Anticuerpos Monoclonales Humanizados / Neoplasias de la Mama Triple Negativas Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Cancer Año: 2020 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google